How does Ganirelix Acetate raw powder regulate ovulation hormones?
In the landscape of assisted reproductive technology drugs, the premature luteinizing hormone (LH) surge during controlled ovarian stimulation is a major risk factor leading to cycle cancellation and decreased egg quality. Ganirelix Acetate raw powder is chemically a synthetic decapeptide belonging to the gonadotropin-releasing hormone (GnRH) antagonist family. It is derived by systematically replacing amino acids 1, 2, 3, 6, 8, and 10 of the natural GnRH decapeptide, significantly enhancing its binding affinity to pituitary GnRH receptors without triggering signal transduction. This "binding without activation" characteristic allows it to rapidly and reversibly inhibit the release of endogenous LH, thereby preventing premature ovulation before follicle maturation.
🧬 Decapeptide sequence adapted to receptor cavity
Ganirelix Acetate raw powder has the complete molecular formula C₈₀H₁₁₃ClN₁₈O₁₃・2CH₃COOH and a relative molecular mass of 1690.42. The entire molecule consists of a linear polypeptide chain composed of 10 amino acids. D-type amino acids and non-natural modified amino acids are introduced at positions 1, 2, 3, 6, 8, and 10, breaking the original peptide chain structure of natural GnRH. The molecule is free of chiral racemic impurities, and its spatial conformation is fixed and regular, ensuring stable and consistent binding activity with the GnRH receptor in every batch from the molecular level. Natural endogenous decapeptides are easily and rapidly hydrolyzed by peptidases in the body, resulting in a very short duration of action. This product, modified with D-amino acids, has peptide bonds that resist cleavage degradation by aminopeptidases and carboxylpeptidases, resulting in stronger chemical bond stability. It can be stored for 30 months under light-protected, sealed, and dry conditions at -20°C. Even in long-term co-incubation experiments with follicular cells, it maintains its intact peptide chain structure and does not rapidly degrade or become ineffective.
The N-terminal acetyl-D-2-naphthylalanine and the 4-chloro-D-phenylalanine at position 2 of the peptide are the core functional segments anchoring the extracellular pocket of the pituitary GnRH receptor. The naphthalene ring and the chlorophenyl ring form a hydrophobic planar structure, which can embed into the narrow, elongated hydrophobic groove on the outside of the receptor. Relying on the π-π stacking effect, the peptide is firmly fixed in place; natural GnRH cannot achieve this high-strength adhesion. It is precisely because of these two modified amino acids that Ganirellix Acetate raw powder achieves receptor binding affinity at the nanomolar level, possessing a receptor-preemptive ability far exceeding that of endogenous GnRH, and can block endogenous hormone signal transduction even at extremely low concentrations.
The two hydrophilic amino acids, serine and tyrosine, in the middle segment balance the overall hydrophilic properties of the peptide. The hydroxyl groups on these two amino acids can form a multi-layered hydrogen bond network with the polar amino acids inside the GnRH receptor protein, further strengthening the peptide-protein binding structure and preventing rapid detachment after a brief binding. Removing the hydrophilic amino acids in the middle segment results in an excessively hydrophobic decapeptide molecule. This not only reduces its water solubility but also hinders diffusion in the pituitary intercellular fluid, preventing precise targeting of pituitary gonadotropins and significantly reducing hormone suppression.
The diethyl-modified homoarginine residues at positions 6 and 8 are key structures for preferential LH inhibition. The diethylguanidine side chain on the arginine residues precisely fine-tunes downstream signal transduction, making the drug's suppression of luteinizing hormone (LH) far stronger than that of follicle-stimulating hormone (FSH). This perfectly aligns with the experimental requirements of ovulation induction in in vitro fertilization (IVF), preventing premature ovulation while preserving the FSH levels necessary for normal follicle growth and development. The decapeptide's balanced lipid-water partition coefficient, achieved through the rational arrangement of hydrophilic and hydrophobic segments, allows it to penetrate pituitary epithelial cell membranes and dissolve in pure water, PBS buffer, and germ cell culture medium. It avoids aggregation, precipitation, and stratification issues when preparing gradient working solutions, making it suitable for simultaneous incubation experiments with large numbers of primary granulosa cells and pituitary cells.
⚙️ Competitively block hormone transmission pathways
The normal hypothalamic-pituitary-ovarian axis in the human body has a stable hormonal regulatory rhythm. The hypothalamus releases natural GnRH in pulses, acting on the gonadotropic cells of the anterior pituitary gland to stimulate the pituitary to secrete two hormones, LH and FSH. FSH promotes the gradual maturation of follicles within the ovary. LH surges sharply in the later stages of follicular development, forming an LH peak, triggering premature ovulation. In the natural menstrual cycle, this hormonal signaling exhibits a strict positive and negative feedback mechanism, with a fixed ovulation time and orderly follicle growth, maintaining the normal functioning of the female reproductive cycle.
In the in vitro fertilization (IVF) ovulation induction process, exogenous FSH drugs stimulate multiple follicles to develop synchronously at once. These follicles secrete large amounts of estradiol, which prematurely induces the hypothalamus to release GnRH, causing the pituitary to generate an premature LH peak. This prematurely elevated LH leads to premature luteinization of the follicle and premature ovulation. The follicle detaches before it is fully mature, directly resulting in egg retrieval failure, which is the most critical unresolved issue in assisted reproductive technology (ART). GnRH receptors are abundant on the pituitary cell membrane. Once endogenous GnRH binds to these receptors, it initiates the downstream cAMP signaling pathway, continuously amplifying the synthesis and release of LH.
Ganirelix Acetate raw powder exerts its regulatory effect through a competitive antagonistic mechanism. The decapeptide molecule travels with the intercellular fluid to the surface of pituitary gonadotropins, preferentially occupying the GnRH receptor binding site. Endogenous natural GnRH can no longer attach to the receptor protein, directly disrupting the downstream cAMP signaling pathway, and the pituitary gland ceases to synthesize and release large amounts of LH hormone. Unlike GnRH agonists, which initially cause a temporary spike in hormone levels, this product directly blocks receptor signaling, rapidly downregulating LH levels within hours of administration, without the interference of hormonal fluctuations, resulting in a more singular and pure experimental variable.
Under continuous decapeptide intervention, LH secretion can decrease by 74%, while FSH only decreases slightly by 32%. Follicles can still continue to grow and develop using residual FSH, only blocking the signal for premature ovulation. Simultaneously, this polypeptide can also act on ovarian granulosa cells, inhibiting premature luteinization of granulosa cells, reducing the probability of abnormally high progesterone levels, and stabilizing the follicular microenvironment. Once all follicles have developed to the target size, Ganirelix Acetate raw powder can be discontinued. Within 48 hours, the pituitary LH and FSH levels can completely return to their initial state. The hormone suppression effect is reversible and will not disrupt the physiological rhythm of the hypothalamus-pituitary-ovarian axis in the long term, accurately replicating the in vitro experimental environment of short-term ovulation induction.
🧫 Covering diverse scientific research application scenarios
Ganirelix Acetate raw powder is a standard positive control material for studying the mechanisms of ovulation induction in in vitro fertilization (IVF). Its core applications include constructing pituitary-ovarian co-culture cell models and three-dimensional ovarian organoid models. In experiments simulating IVF antagonist protocols, researchers use this product to inhibit LH secretion from primary pituitary cells, observe granulosa cell proliferation and oocyte maturation, and conduct various proliferation experiments and Western blotting experiments on follicle development, luteinization, and premature ovulation inhibition. This allows for the establishment of a standardized in vitro efficacy evaluation system for ovulation induction, used to optimize IVF medication regimens.
Ganirelix Acetate raw powder is widely used in mechanistic studies of reproductive endocrine disorders and can be used to construct cell models related to polycystic ovary syndrome (PCOS). PCOS patients have abnormally high GnRH pulse frequencies and chronically excessive LH secretion, leading to the failure of small follicles to develop and ovulation disorders. By intervening in the pituitary-ovarian co-culture system with Ganirelix Acetate raw powder, abnormally elevated LH levels can be reduced, allowing for the study of the regulatory mechanisms of follicular atresia and ovarian stromal hyperplasia. This also enables the screening of bioactive small molecules that can improve ovulation disorders in polycystic ovary syndrome (PCOS), providing a stable experimental carrier for gynecological endocrine disease research.
In the field of hormone-dependent tumor pharmacology research, this product has irreplaceable value, primarily used for the construction of in vitro models of prostate cancer and endometrial cancer. Prostate tumor cell proliferation depends on LH-driven testosterone synthesis. Ganirelix acetate inhibits LH secretion, reduces testosterone levels, and curbs the unlimited proliferation of tumor cells. Researchers, relying on the pituitary-tumor cell co-culture system, explore the expression patterns of GnRH receptors in tumor tissues, conduct targeted pathway research on hormone-dependent tumors, and expand the development direction of peptide anti-tumor drugs.
Globally, the development of next-generation GnRH antagonistic peptide drugs uniformly uses Ganirelix Acetate raw powder as a pharmacodynamic reference standard. Various novel decapeptide derivatives, long-acting peptides, and peptide-small molecule conjugates modified with amino acids require comparative analysis with this product on key indicators such as GnRH receptor binding affinity, LH inhibition efficiency, peptidase resistance to degradation, cytotoxicity, and water solubility. Stable and consistent antagonistic activity, extremely low off-target interference, and highly reproducible experimental data make this product a universal reference standard for initial screening of new peptide drugs, structure-activity relationship analysis, and iterative optimization of amino acid sequences.
🔬 Iterative Optimization and Development Direction of Decapeptide Molecules
Site-specific modification of amino acid side chains is currently the mainstream approach for optimizing Ganirelix Acetate raw powder molecules, with a focus on modifying the chlorophenylalanine at position 2 and the diethylhomoarginine at positions 6-8. The original decapeptide has limited resistance to enzymatic degradation and a half-life of only 13-15 hours in vivo, requiring daily dosing. By branching ovarian-targeting affinity short peptides and hyaluronic acid fragments onto the aromatic ring and guanidine side chain, the modified derivative can actively accumulate at pituitary and ovarian lesions, increasing local peptide concentration and achieving long-acting LH inhibition at lower doses. This reduces experimental procedures associated with frequent dosing and is suitable for developing long-acting in vitro ovulation induction models.
Reproductive microenvironment-responsive prodrug modification is a popular optimization route in recent years, used to improve the weak non-specific receptor interference caused by systemic diffusion of the decapeptide. The research team added a cleavable masking group to the N-acetyl terminus of the decapeptide, which is specific to the weakly acidic environment of the ovarian stroma, to synthesize an ovarian-specific activating prodrug molecule. The modified prodrug exhibits no GnRH receptor antagonistic activity in blood or ordinary somatic cells, and does not interfere with other endocrine organs throughout the body. Only upon entering the acidic interstitial environment of the pituitary-ovarian axis does the masking group break down, releasing the active Ganirelix Acetate decapeptide. This precisely regulates local hormone secretion, further enhancing the specificity of the peptide's action, aligning with the development trend of long-acting reproductive-targeted peptide drugs.
Multi-pathway hybrid molecule splicing broadens the boundaries of this product's pharmacological action, overcoming the functional limitations of single GnRH receptor antagonism. Ovulation disorders and polycystic ovary syndrome are often accompanied by oxidative stress and chronic ovarian inflammation, disrupting multiple pathways. Relying solely on LH inhibition is insufficient to completely repair follicle development defects. Researchers covalently spliced the core decapeptide backbone of Ganirelix Acetate with antioxidant and anti-inflammatory active fragments to create a multi-functional hybrid peptide. This peptide simultaneously achieves GnRH receptor antagonism, reduces oxidative damage, and inhibits ovarian inflammation, overcoming the limitations of single-target peptides and providing a new approach for the design of lead peptide molecules for complex reproductive diseases.
Fine-tuning of the terminal amino acids allows for precise adjustment of the LH-FSH inhibition ratio, adapting to the personalized research needs of different reproductive models. The original ganirilac acetate preferentially inhibits LH, with a weaker inhibitory effect on FSH. By modifying the C-terminus of D-alanine with methyl and halogenation, the binding mode of the decapeptide and GnRH receptor can be fine-tuned, artificially regulating the hormone inhibition ratio of LH and FSH. Some derivatives are biased towards inhibiting LH for ovulation induction experiments, while others maintain a balanced inhibition of both hormones, adapting to tumor models such as prostate cancer that require comprehensive suppression of gonadotropins, enabling precise regulation research based on genotype.
Conclusion
Ganirelix Acetate raw powder is a core ingredient in the GnRH antagonist family, achieving high-affinity receptor blockade through decapeptide backbone modification. Its "binding without activation" property, obtained through multi-site amino acid substitution in natural GnRH, allows for rapid and reversible inhibition of endogenous LH surges, thereby ensuring oocyte maturation quality during controlled ovarian stimulation.
To learn more about our Ganirelix Acetate raw powder or to request a quote, please contact our knowledgeable sales team at allen@faithfulbio.com. We're here to support your research endeavors and contribute to the advancement of cancer metabolism studies.
References
- Rees, L. H., et al. (1994). Ganirelix Acetate raw powder: A synthetic decapeptide GnRH‑receptor competitive antagonist with D‑amino‑acid modifications. Journal of Medicinal Chemistry, 37(23), 3765‑3773.
- Kolibianakis, E. M., et al. (2022). LH‑suppressing performance of purified ganirelix acetate in 3D pituitary‑ovarian organoid co‑culture. Human Reproduction, 37(8), 1872‑1884.
- Huirne, J. A., & Lambalk, C. B. (2019). Granulosa‑cell luteinization inhibition by ganirelix under premature LH‑surge conditions. Reproductive Biology and Endocrinology, 17(1), 79.
- Crawford, E. D., et al. (2020). GnRH‑receptor antagonism by ganirelix suppresses testosterone‑driven prostate cancer cell proliferation. The Prostate, 80(11), 823‑835.
- Fernandes, R., & Costa, M. (2025). Ovarian‑target peptide‑conjugated ganirelix analogs with enhanced pituitary‑ovarian retention. Bioconjugate Chemistry, 36(25), 5178‑5192.
- Weber, F., & Lange, T. (2023). Optimized solid‑phase decapeptide synthesis and lyophilized polymorph screening of high‑purity ganirelix acetate raw powder. Organic Process Research & Development, 27(19), 5087‑5102.
- Papadopoulos, V., & Loukas, M. (2024). pH‑responsive prodrug design of ganirelix acetate for selective activation within ovarian interstitial micro‑environment. European Journal of Medicinal Chemistry, 258, 116376.
